Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.39 |
| ▸ | RARB | P10826 | 2/20 | 0.36 |
| ▸ | RARG | P13631 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | RXRB | P28702 | 2/20 | 0.36 |
| ▸ | RXRG | P48443 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20614418 | 0.86 | DAO (0.52) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL262357 | 0.84 | CSNK2A2 (0.41) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL2064339 | 0.81 | DAO (0.59) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL20828959 | 0.74 | HPGD (0.32) | HPGD | |
| SCHEMBL835069 | 0.71 | DAO (1.00) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL3093344 | 0.70 | DAO (0.65) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL31612455 | 0.69 | MAPT (0.39) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL1472954 | 0.68 | DAO (0.63) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL1529585 | 0.68 | DAO (1.00) | DAOKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL7431737 | 0.66 | CSNK2A2 (0.43) | DAOKDM4EMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101528726-B | Thiophene derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD | 2012-11-14 | — | — | CN | disclosed |
| EP-2069322-B1 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-8133910-B2 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| US-8133910-B2 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| US-8133910-B2 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-25 | — | — | US | disclosed |
| CN-101528726-A | Thiophene derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-09 | — | — | CN | disclosed |
| EP-2069322-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008029306-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008029306-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | S1PR1, S1PR3, S1PR2 | DAO 4844/4885KDM4E 1389/4885MAPT 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.